Download PDF
Horm Metab Res 2021; 53(07): 478-484
DOI: 10.1055/a-1492-3077
Endocrine Care

Resistin is Associated with Inflammation and Renal Function, but not with Insulin Resistance in Type 2 Diabetes

Łukasz Rzepa
1   1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Michał Peller
1   1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Ceren Eyileten
2   Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
,
Marek Rosiak
3   Department of Cardiology and Hypertension, Central Clinical Hospital, Warsaw, Poland
,
Agnieszka Kondracka
4   Department of Internal Diseases and Endocrinology, Medical University of Warsaw, Warsaw, Poland
,
Dagmara Mirowska-Guzel
2   Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
,
Grzegorz Opolski
1   1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Krzysztof J. Filipiak
1   1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
,
Marek Postuła
2   Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
,
Agnieszka Kapłon-Cieslicka
1   1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
› Author Affiliations Funding: The AVOCADO study was implemented with MUW and CEPT infrastructure, and supported financially partly by the European Union – the European Regional Development Fund within the Operational Program “Innovative Economy” for 2007–2013 – and by the research grant from the Polish Pharmaceutical Company ADAMED for a Young Scientist 2007 Award.
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim of the study was to investigate the association of adipokines (resistin, leptin and adiponectin) with obesity, insulin resistance (IR) and inflammation in type 2 diabetes mellitus (T2DM). A total of 284 patients with T2DM were included. Concentrations of resistin, leptin, adiponectin, and inflammatory markers [high sensitivity C-reactive protein (hsCRP), tumor necrosis factor α (TNF-α), and interleukin 6 (IL-6)] were measured and homeostatic model assessment for IR (HOMA-IR) index was calculated. Resistin correlated negatively with estimated glomerular filtration rate (eGFR) and positively with hsCRP, TNF-α, IL-6, and white blood cell count (WBC). Leptin correlated positively with HOMA-IR, whereas adiponectin correlated negatively. Leptin also correlated positively with body mass index (BMI), waist circumference, IL-6, WBC and negatively with eGFR. Adiponectin correlated negatively with waist circumference, WBC, and eGFR. Multivariate logistic regression indicated lower eGFR and higher WBC and IL-6 as independent predictive factors of resistin concentration above the upper quartile (CAQ3), whereas female sex and higher BMI and HOMA-IR of leptin CAQ3, and lower HOMA-IR and older age of adiponectin CAQ3. In conclusion, in contrast to leptin and adiponectin, in T2DM patients, resistin is not associated with BMI and IR, but with inflammation and worse kidney function.

Key words

resistin - adipokines - diabetes mellitus - inflammation - renal function - insulin resistance

Supplementary Material



Publication History

Received: 01 December 2020

Accepted after revision: 19 April 2021

Article published online:
24 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Saeedi P, Petersohn I, Salpea P. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107843
    CrossrefPubMedGoogle Scholar
  • 2 [Anonymous] Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S14-S31
    CrossrefPubMedGoogle Scholar
  • 3 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323
    CrossrefPubMedGoogle Scholar
  • 4 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
    CrossrefPubMedGoogle Scholar
  • 5 Kocot J, Dziemidok P, Kielczykowska M. et al. Adipokine Profile in Patients with Type 2 Diabetes Depends on Degree of Obesity. Med Sci Monitor 2017; 23: 4995-5004
    CrossrefPubMedGoogle Scholar
  • 6 Liu W, Zhou X, Li Y. et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: A population-based study. Medicine 2020; 99: e19052
    CrossrefPubMedGoogle Scholar
  • 7 Kontunen P, Vuolteenaho K, Nieminen R. et al. Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheumatol 2011; 40: 256-262
    CrossrefPubMedGoogle Scholar
  • 8 Kaplon-Cieslicka A, Postula M, Rosiak M. et al. Association of adipokines and inflammatory markers with lipid control in type 2 diabetes. Polsk Arch Med Wewnetr 2015; 125: 414-423
    PubMedGoogle Scholar
  • 9 Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445
    CrossrefPubMedGoogle Scholar
  • 10 Moreno LO, Salvemini L, Mendonca C. et al. Serum resistin and glomerular filtration rate in patients with type 2 diabetes. PLoS One 2015; 10: e0119529
    CrossrefPubMedGoogle Scholar
  • 11 Steppan CM, Bailey ST, Bhat S. et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
    CrossrefPubMedGoogle Scholar
  • 12 Huang X, Yang Z. Resistin’s, obesity and insulin resistance: The continuing disconnect between rodents and humans. J Endocrinol Invest 2016; 39: 607-615
    CrossrefPubMedGoogle Scholar
  • 13 Cebeci E, Cakan C, Gursu M. et al. The Main determinants of serum resistin level in type 2 diabetic patients are renal function and inflammation not presence of microvascular complication, obesity and insulin resistance. Exp Clin Endocrinol Diabetes 2019; 127: 189-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Axelsson J, Bergsten A, Qureshi AR. et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69: 596-604
    CrossrefPubMedGoogle Scholar
  • 15 Kawamura R, Doi Y, Osawa H. et al. Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study. Nephrol Dialysis Transplant 2010; 25: 3236-3240
    CrossrefPubMedGoogle Scholar
  • 16 German JP, Wisse BE, Thaler JP. et al. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010; 59: 1626-1634
    CrossrefPubMedGoogle Scholar
  • 17 Moon HU, Ha KH, Han SJ. et al. The Association of adiponectin and visceral fat with insulin resistance and beta-cell dysfunction. J Kor. Med Sci 2019; 34: e7
    PubMedGoogle Scholar
  • 18 Uslu S, Kebapci N, Kara M. et al. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Therap Med 2012; 4: 113-120
    CrossrefPubMedGoogle Scholar
  • 19 Postula M, Kaplon-Cieslicka A, Rosiak M. et al. Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: Evaluation of 27 polymorphisms within candidate genes. J Thromb Haemost 2011; 9: 2291-2301
    CrossrefPubMedGoogle Scholar
  • 20 Rosiak M, Postula M, Kaplon-Cieslicka A. et al. The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: A subanalysis of the AVOCADO study. Kardiol Pol 2013; 71: 552-557
    CrossrefPubMedGoogle Scholar
  • 21 Kaplon-Cieslicka A, Rosiak M, Postula M. et al. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol 2013; 71: 893-902
    CrossrefPubMedGoogle Scholar
  • 22 Kaplon-Cieslicka A, Postula M, Rosiak M. et al. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. Cardiovasc Diabetol 2014; 13: 112
    CrossrefPubMedGoogle Scholar
  • 23 Kaplon-Cieslicka A, Tyminska A, Rosiak M. et al. Resistin is a prognostic factor for death in type 2 diabetes. Diabetes/Metab Res Rev 2019; 35: e3098
    CrossrefPubMedGoogle Scholar
  • 24 Postula M, Janicki PK, Rosiak M. et al. New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: Genome-wide association approach and pooled DNA strategy. J Thromb Thrombol 2013; 36: 65-73
    CrossrefPubMedGoogle Scholar
  • 25 Eyileten C, Zaremba M, Janicki PK. et al. Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity but not to Genetic Polymorphisms within BDNF Encoding Gene in Patients with Type 2 Diabetes. Med Sci Monitor 2016; 22: 69-76
    CrossrefPubMedGoogle Scholar
  • 26 Milanowski L, Pordzik J, Janicki PK. et al. New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study. Acta Diabetol 2017; 54: 343-351
    CrossrefPubMedGoogle Scholar
  • 27 Eyileten C, Mirowska-Guzel D, Milanowski L. et al. Serum brain-derived neurotrophic factor is related to platelet reactivity and metformin treatment in adult patients with type 2 diabetes mellitus. Canad J Diabetes 2019; 43: 19-26
    CrossrefPubMedGoogle Scholar
  • 28 Park HK, Kwak MK, Kim HJ. et al. Linking resistin, inflammation, and cardiometabolic diseases. Kor J Intern Med 2017; 32: 239-247
    CrossrefPubMedGoogle Scholar
  • 29 Patel L, Buckels AC, Kinghorn IJ. et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476
    CrossrefPubMedGoogle Scholar
  • 30 Engin A. The Pathogenesis of Obesity-Associated Adipose Tissue Inflammation. Adv Exp Med Biol 2017; 960: 221-245
    CrossrefPubMedGoogle Scholar
  • 31 Park H, Hasegawa G, Obayashi H. et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chim Acta 2006; 374: 129-134
    CrossrefPubMedGoogle Scholar
  • 32 Chen BH, Song Y, Ding EL. et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009; 32: 329-334
    CrossrefPubMedGoogle Scholar
  • 33 Su KZ, Li YR, Zhang D. et al. Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: A systematic review and meta-analysis. Front Physiol 2019; 10: 1399
    CrossrefPubMedGoogle Scholar
  • 34 Bellia C, Cosma C, Lo Sasso B. et al. Glycated albumin as a glycaemic marker in patients with advanced chronic kidney disease and anaemia: a preliminary report. Scand J Clin Lab Invest 2019; 79: 293-297
    CrossrefPubMedGoogle Scholar
  • 35 Filkova M, Haluzik M, Gay S. et al. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol (Orlando, Fla) 2009; 133: 157-170
    CrossrefPubMedGoogle Scholar
  • 36 Mostafazadeh M, Haiaty S, Rastqar A. et al. Correlation Between Resistin Level and Metabolic Syndrome Component: A Review. Horm Metab Res 2018; 50: 521-536
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Acquarone E, Monacelli F, Borghi R. et al. Resistin: A reappraisal. Mech Ageing Develop 2019; 178: 46-63
    CrossrefPubMedGoogle Scholar
  • 38 Pine GM, Batugedara HM, Nair MG. Here, there and everywhere: Resistin-like molecules in infection, inflammation, and metabolic disorders. Cytokine 2018; 110: 442-451
    CrossrefPubMedGoogle Scholar
  • 39 Li B, Fang J, Zuo Z. et al. Activation of the porcine alveolar macrophages via toll-like receptor 4/NF-kappaB mediated pathway provides a mechanism of resistin leading to inflammation. Cytokine 2018; 110: 357-366
    CrossrefPubMedGoogle Scholar
  • 40 Zuniga MC, Raghuraman G, Hitchner E. et al. PKC-epsilon and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages. Atherosclerosis 2017; 259: 51-59
    CrossrefPubMedGoogle Scholar
  • 41 Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016; 12: 73-81
    CrossrefPubMedGoogle Scholar
  • 42 Landray MJ, Wheeler DC, Lip GY. et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
    CrossrefPubMedGoogle Scholar
  • 43 Kielstein JT, Becker B, Graf S. et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42: 62-66
    CrossrefPubMedGoogle Scholar
  • 44 Frankel DS, Vasan RS, D'Agostino RB. et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am College Cardiol 2009; 53: 754-762
    CrossrefPubMedGoogle Scholar
  • 45 Ramirez JL, Khetani SA, Zahner GJ. et al. Serum resistin is associated with impaired endothelial function and a higher rate of adverse cardiac events in patients with peripheral artery disease. J Vasc Surg 2019; 69: 497-506
    CrossrefPubMedGoogle Scholar
  • 46 Abdella NA, Mojiminiyi OA, Moussa MA. et al. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diab Med 2005; 22: 278-285
    CrossrefPubMedGoogle Scholar
  • 47 Horakova D, Stepanek L, Nagelova R. et al. Total and high-molecular-weight adiponectin levels and prediction of insulin resistance. Endokrynol Pol 2018; 69: 375-380
    PubMedGoogle Scholar
  • 48 Lee JM, Kim SR, Yoo SJ. et al. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res 2009; 37: 1803-1812
    CrossrefPubMedGoogle Scholar
  • 49 Kaleta D, Makowiec-Dabrowska T, Dziankowska-Zaborszczyk E. et al. Prevalence and socio-demographic correlates of daily cigarette smoking in Poland: results from the Global Adult Tobacco Survey (2009-2010). Int J Occup Med Environ Health 2012; 25: 126-136
    PubMedGoogle Scholar
  • 50 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
    CrossrefPubMedGoogle Scholar
  • 51 Sarafidis PA, Lasaridis AN, Nilsson PM. et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens 2007; 21: 709-716
    CrossrefPubMedGoogle Scholar